Sort
59,101 grants matching “hypertension”
Assessment of Policies through Prediction of Long-term Effects on Cardiovascular Disease Using Simulation (APPLE CDS)
$897,090Yan Li · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · HL
Improving Pediatric Cardiac Arrest Survival and Neurologic Outcome
$897,005Todd Justen Kilbaugh · Children'S Hosp Of Philadelphia · R01 · FY2019 · HL
Obesity, related comorbidities, and breast cancer outcomes in African Americans
$896,846Elisa V Bandera · Rbhs -Cancer Institute Of New Jersey · R01 · FY2014 · CA
Nutrition and Physical Activity Assessment Study (NPAAS)
$896,761Marian L Neuhouser · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Contemporary Classification of Myocardial Injury Events in MESA: Defining Distinct Risk Factor Associations with Myocardial Infarction Type 1-5 and Acute Non-Ischemic Myocardial Injury
$896,650Andrew Defilippis · Vanderbilt University Medical Center · R01 · FY2022 · HL
EXTENDED RELEASE TORSEMIDE: PHASE 2
$896,260Peter Uri Feig · Sarfez Pharmaceuticals, Inc. · R44 · FY2015 · DK
Mechanisms that Predict Weight Trajectory after Bariatric Surgery: The Interactive Roles of Behavior and Biology
$896,062Kristine Jayne Steffen · North Dakota State University · R01 · FY2018 · DK
Transmembrane Signaling Mechanisms Involving TRP Channels
$895,958Lutz Birnbaumer · National Institute Of Environmental Health Sciences · ZIG · FY2010 · ES
Controlled Trial of Renin Angiotensin Blockade in ADPKD
$895,775Vicente E Torres · Mayo Clinic Rochester · U01 · FY2013 · DK
Animal MRI/MRS Methodological Development for Drug Addiction Applications
$895,501Yihong Yang · National Institute On Drug Abuse · ZIA · FY2010 · DA
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates
$895,365Suchismita Acharya · Ayuvis Research, Inc. · R44 · FY2024 · HD
Mechanisms of sphingolipid signaling in vascular health and disease
$894,683Timothy Tun Hla · Boston Children'S Hospital · R35 · FY2021 · HL
Antifibrotic Therapy for the Treatment of Pulmonary Hypertension
$894,567Philip Sanderson · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR
Behavioral Economic Approaches to Increase Physical Activity among Patients with Elevated Risk for Cardiovascular Disease
$894,130Kevin G Volpp · University Of Pennsylvania · R33 · FY2021 · HL
i2b2: New Driving Biological Projects (To Be Named)
$893,724Isaac S. Kohane · Brigham And Women'S Hospital · U54 · FY2007 · LM
Effects of vascular risk factors on risk for dementia and stroke after late-onset epilepsy (EpilepsyCOG)
$893,219Hyunmi Choi · Columbia University Health Sciences · R01 · FY2022 · AG
Mediators of fatty liver disease during HIV/SIV and cART treatment
$893,138Donald L Sodora · Seattle Children'S Hospital · R01 · FY2019 · AI
Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
$892,710Gordon H Williams · Brigham And Women'S Hospital · R01 · FY2010 · HL
Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT (Optimize-SPRINT)
$892,656Andrew Edward Moran · Columbia University Health Sciences · R01 · FY2018 · HL
Hypertension Pharmacogenetics
$892,652University Of Florida · R01 · FY2003 · HL
ARIC Neurocognitive Study (ARIC-NCS)
$892,596Aaron R Folsom · University Of Minnesota · U01 · FY2016 · HL
Illuminating the path(ophysiology) to development of youth-onset type 2 diabetes (PATH-NC)
$892,561Elizabeth T Jensen · Wake Forest University Health Sciences · U01 · FY2024 · DK
Gulf Longitudinal Follow-up (GuLF) Study
$892,530Dale P Sandler · National Institute Of Environmental Health Sciences · ZIA · FY2025 · ES
Role of Gs-alpha in central regulation of energy and glucose metabolism
$892,392Lee Weinstein · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Delay discounting as a target for self-regulation in prediabetes
$892,075Leonard H Epstein · State University Of New York At Buffalo · UH2 · FY2015 · DK